Coherus Oncology (CHRS) EBT Margin (2013 - 2026)
Coherus Oncology (CHRS) reported EBT Margin of 300.04% for Q1 2026, up 32370.0% on a YoY basis from N/an in Q1 2025, and up 17.47% sequentially from 363.56% in Q4 2025.
Coherus Oncology (CHRS) EBT Margin (2013 - 2026) Analysis & Trends
Coherus Oncology (CHRS) has 13 years of EBT Margin data on file, last reported at 300.04% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 32370.0% year-over-year to 300.04%; the trailing twelve-month figure through Mar 2026 stood at 368.28% (up 25022.0% YoY), and the FY2025 full-year result was 434.23%, up 38200.0% from the prior year.
- EBT Margin grew to 300.04% in Q1 2026, from 363.56% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 53.67% in Q3 2023 to a low of 2947.83% in Q1 2024.
- A 5-year average of 469.63% and a median of 300.04% in 2026 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 271436 bps in 2024 and jumped 232409 bps in 2025, its largest moves.
- Tracing CHRS's EBT Margin over 5 years: stood at 129.81% in 2022, then surged by 33 bps to 87.03% in 2023, then plunged by 585 bps to 596.06% in 2024, then surged by 39 bps to 363.56% in 2025, then climbed by 17 bps to 300.04% in 2026.
- Business Quant data shows CHRS's EBT Margin at 300.04% in Q1 2026, 363.56% in Q4 2025, and 384.73% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Coherus Oncology | 195.05 Mn | 28.00 Mn | 8.50 Mn | -300.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300.04% |
| Dec 31, 2025 | -363.56% |
| Sep 30, 2025 | -384.73% |
| Jun 30, 2025 | -437.51% |
| Mar 31, 2025 | -623.74% |
| Dec 31, 2024 | -596.06% |
| Sep 30, 2024 | -786.50% |
| Jun 30, 2024 | -532.74% |
| Mar 31, 2024 | -2,947.83% |
| Dec 31, 2023 | -87.03% |
| Sep 30, 2023 | -53.67% |
| Jun 30, 2023 | -73.01% |
| Mar 31, 2023 | -233.47% |
| Dec 31, 2022 | -129.81% |
| Sep 30, 2022 | -190.76% |
| Jun 30, 2022 | -83.37% |
| Mar 31, 2022 | -159.83% |
| Dec 31, 2021 | -62.28% |
| Sep 30, 2021 | -46.70% |
| Jun 30, 2021 | -34.12% |